Fresenius SE & Co. KGaA

M&A Activity • Jan 7, 2005

News Details

Ad-hoc | 7 January 2005 07:27

Fresenius AG:Fresenius Kabi acquires Labesfal

Ad hoc announcement §15 WpHG Acquisition Fresenius AG:Fresenius Kabi acquires Labesfal Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Fresenius Kabi acquires Labesfal Fresenius Kabi continues growth strategy and acquires I.V. drug company The Management Board of Fresenius AG announced today that on January 7, 2005 Fresenius Kabi AG, a subsidiary of Fresenius AG, has signed an agreement to acquire Labesfal – Laboratório de Especialidades Farmacêuticas Almiro S.A. The company is headquartered in Campo de Besteiros in central Portugal and offers intravenously administered drugs (I.V. drugs) for the domestic market. This acquisition will significantly expand the I.V. drug portfolio of Fresenius Kabi, the European market leader in infusion and nutrition therapy. Fresenius Kabi plans to introduce Labesfal’s products throughout Europe. The acquisition is an important step in the company’s growth strategy. In 2004, privately-owned Labesfal achieved sales of EUR 56 million and employed approximately 320 people. The acquisition will be accretive to Fresenius Kabi’s earnings in the first year and will lead to a further improvement in the EBIT margin of the company. Labesfal holds an excellent position on the Portuguese hospital market with a comprehensive product portfolio of generic I.V. drugs such as antibiotics, analgesics and local anesthetics as well as for treating gastrointestinal diseases. Fresenius Kabi is a leader in the development, production and distribution of infusion therapy products for hospitals. Labesfal is an excellent fit in this segment. Fresenius Kabi plans to use its existing sales and marketing network to introduce Labesfal’s I.V. drug products to the European market. The products are expected to receive European regulatory approval within the next two years. The acquisition requires the approval of Portuguese antitrust authorities. The Management Board Bad Homburg v.d.H., January 7, 2005 Fresenius AG Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Deutschland ISIN: DE0005785638;DE000578560 WKN: 578563;578560 Listed: Frankfurt; Amtlicher Markt in Düsseldorf, Frankfurt (Prime Standard) und München; Freiverkehr in Berlin-Bremen, Hamburg und Stuttgart End of ad hoc announcement (c)DGAP 07.01.2005 070727 Jän 05